Skip to main content

A PHASE 1, MULTI-CENTER, OPEN-LABEL, DOSE FINDING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF CC-94676 IN SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Clinical Trial Grant
Duke Scholars

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

January 18, 2021

End Date

January 14, 2026
 

Administered By

Duke Cancer Institute

Awarded By

Celgene Corporation

Start Date

January 18, 2021

End Date

January 14, 2026